Nafarelin

Gonadotropin Releasing Hormone Receptor Agonist — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Nafarelin is a drug in the Gonadotropin Releasing Hormone Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1990. Its mechanism of action is classified as Gonadotropin Releasing Hormone Receptor Agonists. DrugCentral lists 1 molecular target, including GNRHR. Recorded indications include Endometriosis, Precocious puberty and Prevention of premature ovulation.

• Drug class: Gonadotropin Releasing Hormone Receptor Agonist.
• Mechanism of action: Gonadotropin Releasing Hormone Receptor Agonists.
• Molecular targets: GNRHR (1 listed in DrugCentral).
• Indications: Endometriosis, Precocious puberty and Prevention of premature ovulation.
• ATC code: H01CA02 (Gonadotropin-releasing hormones).
• Molecular formula: C66H83N17O13; molecular weight 1322.50 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Endometriosis
• Precocious puberty
• Prevention of premature ovulation

Contraindications (13)

• Alcoholism
• Breastfeeding (mother)
• Cardiovascular event risk
• Diabetes mellitus
• Hypercholesterolemia
• Hyperglycemia
• Hypertensive disorder
• Intermenstrual bleeding - irregular
• Obesity
• Osteopenia
• Osteoporosis
• Pregnancy, function
• Smokes tobacco daily

Mechanism & targets

• Mechanism of action (MoA): Gonadotropin Releasing Hormone Receptor Agonists
• Established pharmacologic class: Gonadotropin Releasing Hormone Receptor Agonist

Molecular targets (1)

Target	Gene	Action	Activity
Gonadotropin-releasing hormone receptor	GNRHR	agonist	Kd 9.70

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2022-08-24	PMDA	—	Pfizer Japan Inc
1990-02-13	FDA	—	GD SEARLE LLC

ATC classification

ATC code	Therapeutic hierarchy
H01CA02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › HYPOTHALAMIC HORMONES › Gonadotropin-releasing hormones

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Ovarian hyperstimulation syndrome	415.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nafarelin is on its molecule page.

• Molecular formula: C₆₆H₈₃N₁₇O₁₃
• Molecular weight: 1322.50 g/mol
• CAS number: 76932-56-4
• InChIKey: RWHUEXWOYVBUCI-ITQXDASVSA-N
• PubChem CID: 25077405

CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nafarelin used for?

DrugCentral lists the following indications for Nafarelin: Endometriosis, Precocious puberty and Prevention of premature ovulation.

How does Nafarelin work?

Nafarelin is classified as Gonadotropin Releasing Hormone Receptor Agonists; its molecular targets in DrugCentral include GNRHR (agonist).

When was Nafarelin first approved?

Nafarelin was first approved by the FDA in 1990.

What drug class does Nafarelin belong to?

Nafarelin is in the Gonadotropin Releasing Hormone Receptor Agonist class.

What is the chemical formula of Nafarelin?

Nafarelin has the molecular formula C66H83N17O13 and a molecular weight of 1322.50 g/mol.

Sources

• DrugCentral drug card 1868 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200671 — compound record and bioactivity
• PubChem CID 25077405 — chemical identifiers
• DrugBank DB00666 — drug record
• FDA UNII 1X0094V6JV — substance identity
• DailyMed: FDA labels for Nafarelin — current prescribing information (label search)
• UniProt P30968 (GNRHR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.